Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
Robert H. I. Andtbacka, Frances Collichio, Kevin J. Harrington et al. · Journal for ImmunoTherapy of Cancer · 2019 · Randomised trial
Full textCC BY